Details

Autor(en) / Beteiligte

• Saraykar, Smita
• Cao, Bo
• Barroso, Lucelia S
• Pereira, Kelly S
• Bertola, Laiss
• Nicolau, Mariana
• Ferreira, Jessica D
• Dias, Natalia S
• Vieira, Erica L
• Teixeira, Antonio L
• Silva, Ana Paula M
• Diniz, Breno S

Titel

Plasma IL-17A levels in patients with late-life depression

Ist Teil von

• Revista brasileira de psiquiatria, 2018-04, Vol.40 (2), p.212-215

Ort / Verlag

Brazil: Associação Brasileira de Psiquiatria

Erscheinungsjahr

2018

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• A consistent body of research has confirmed that patients with major depressive disorder (MDD) have increased concentrations of pro-inflammatory cytokines, including IL-6, TNF-α, IL-1β, the soluble IL-2 receptor, and C-reactive protein, compared to controls; however, there is limited information on IL-17A in MDD. Moreover, information about IL-17A in older populations, i.e., patients with late-life depression (LLD), is conspicuously missing from the literature. The purpose of this study was to investigate the role of IL-17A in LLD. A convenience sample of 129 individuals, 74 with LLD and 55 non-depressed controls, were enrolled in this study. The Mann-Whitney U test was used to compare plasma IL-17A levels between LLD and controls subjects, and Spearman's rank order correlation was used to investigate correlation of these levels with clinical, neuropsychological, and cognitive assessments. Plasma IL-17A levels were not statistically different between LLD patients and controls (p = 0.94). Among all subjects (LLD + control), plasma IL-17A did not correlate significantly with depressive symptoms (rho = -0.009, p = 0.92) but a significant correlation was observed with cognitive assessments (rho = 0.22, p = 0.01). Our findings do not support an association between plasma IL-17A levels and LLD. Nevertheless, IL-17A may be associated with cognitive impairment in LLD patients. If this finding is confirmed in future longitudinal studies, modulation of the T-helper 17 cell (Th17) immune response may be a treatment target for cognitive impairment in this population.